JP2018504117A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504117A5 JP2018504117A5 JP2017538387A JP2017538387A JP2018504117A5 JP 2018504117 A5 JP2018504117 A5 JP 2018504117A5 JP 2017538387 A JP2017538387 A JP 2017538387A JP 2017538387 A JP2017538387 A JP 2017538387A JP 2018504117 A5 JP2018504117 A5 JP 2018504117A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- complex
- fragment
- residue
- forming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15152221.6 | 2015-01-22 | ||
| EP15152221.6A EP3048114A1 (en) | 2015-01-22 | 2015-01-22 | Cytomegalovirus antigens and uses thereof |
| PCT/IB2016/050335 WO2016116904A1 (en) | 2015-01-22 | 2016-01-22 | Cytomegalovirus antigens and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504117A JP2018504117A (ja) | 2018-02-15 |
| JP2018504117A5 true JP2018504117A5 (enExample) | 2019-02-21 |
| JP6717836B2 JP6717836B2 (ja) | 2020-07-08 |
Family
ID=52434568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017538387A Active JP6717836B2 (ja) | 2015-01-22 | 2016-01-22 | サイトメガロウイルス抗原およびその使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10167321B2 (enExample) |
| EP (3) | EP3048114A1 (enExample) |
| JP (1) | JP6717836B2 (enExample) |
| KR (1) | KR20170100039A (enExample) |
| CN (1) | CN107531761B (enExample) |
| AU (2) | AU2016210548B2 (enExample) |
| BE (1) | BE1023087B1 (enExample) |
| BR (1) | BR112017015567A2 (enExample) |
| CA (1) | CA2974041C (enExample) |
| DK (1) | DK3247722T5 (enExample) |
| EA (1) | EA038250B1 (enExample) |
| ES (1) | ES2937959T3 (enExample) |
| FI (1) | FI3247722T3 (enExample) |
| HR (1) | HRP20230177T1 (enExample) |
| HU (1) | HUE061175T2 (enExample) |
| IL (1) | IL253366B (enExample) |
| LT (1) | LT3247722T (enExample) |
| MX (1) | MX382518B (enExample) |
| PL (1) | PL3247722T3 (enExample) |
| PT (1) | PT3247722T (enExample) |
| SG (1) | SG11201705740UA (enExample) |
| SI (1) | SI3247722T1 (enExample) |
| WO (1) | WO2016116904A1 (enExample) |
| ZA (1) | ZA201704912B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201802741T4 (tr) * | 2010-05-14 | 2018-03-21 | Univ Oregon Health & Science | Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları. |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| CN113528466B (zh) | 2014-07-16 | 2024-12-24 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
| JP6816031B2 (ja) | 2015-02-10 | 2021-01-20 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| US11318197B2 (en) | 2016-03-03 | 2022-05-03 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| US11246920B2 (en) | 2016-03-03 | 2022-02-15 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| WO2018067580A1 (en) | 2016-10-03 | 2018-04-12 | Duke University | Methods to identify immunogens by targeting improbable mutations |
| US10532099B2 (en) | 2016-10-18 | 2020-01-14 | Oregon Health & Science University | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| CA3060019A1 (en) * | 2017-04-19 | 2018-10-25 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| WO2019070730A1 (en) | 2017-10-02 | 2019-04-11 | Duke University | MOSAIC ENVELOPES OF HIV-1 TO INDUCE ADCC RESPONSES |
| WO2019169120A1 (en) | 2018-02-28 | 2019-09-06 | University Of Washington | Self-asssembling nanostructure vaccines |
| WO2019195314A2 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Antigenic epstein barr virus polypeptides |
| EP3860650A4 (en) | 2018-10-01 | 2022-06-29 | Duke University | Hiv-1 envelope stabilizing mutations |
| CN113271968B (zh) * | 2018-10-17 | 2024-06-14 | 葛兰素史密丝克莱恩生物有限公司 | 经修饰的巨细胞病毒蛋白和稳定化的复合物 |
| CN109627330A (zh) * | 2018-12-18 | 2019-04-16 | 马鞍山史记动物健康管理有限公司 | 一种猪伪狂犬病毒高效价阳性血清制备方法 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| WO2021014385A1 (en) | 2019-07-24 | 2021-01-28 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
| TWI810589B (zh) * | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
| CN116162154B (zh) * | 2022-10-21 | 2024-06-11 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| EP0945515A3 (en) | 1989-11-06 | 2002-08-21 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
| EP3031469B1 (en) | 2006-06-07 | 2023-08-23 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| DK2352759T3 (en) * | 2008-07-16 | 2017-12-18 | Inst Res Biomedicine | ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUS AND USE THEREOF |
| WO2011027222A2 (en) | 2009-09-02 | 2011-03-10 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
| NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
| WO2012051211A2 (en) | 2010-10-11 | 2012-04-19 | Novartis Ag | Antigen delivery platforms |
| MX350258B (es) | 2011-07-06 | 2017-08-31 | Novartis Ag | Emulsiones cationicas de aceite en agua. |
| TWI570240B (zh) * | 2011-09-09 | 2017-02-11 | 默沙東公司 | 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ |
| CA2878344A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Complexes of cytomegalovirus proteins |
| CA2885145A1 (en) * | 2012-10-30 | 2014-05-08 | Redvax Gmbh | Recombinant particle based vaccines against human cytomegalovirus infection |
| EP3083677B1 (en) | 2013-12-20 | 2019-08-28 | Novartis AG | Novel eukaryotic cells and methods for recombinantly expressing a product of interest |
| JP6708548B2 (ja) | 2013-12-20 | 2020-06-10 | ノバルティス アーゲー | 新規真核細胞および目的の生成物を組換え発現させるための方法 |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| EP3047856A1 (en) | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
-
2015
- 2015-01-22 EP EP15152221.6A patent/EP3048114A1/en not_active Withdrawn
-
2016
- 2016-01-22 PL PL16702210.2T patent/PL3247722T3/pl unknown
- 2016-01-22 SI SI201631665T patent/SI3247722T1/sl unknown
- 2016-01-22 EP EP22203406.8A patent/EP4180056A1/en active Pending
- 2016-01-22 KR KR1020177023123A patent/KR20170100039A/ko not_active Ceased
- 2016-01-22 PT PT167022102T patent/PT3247722T/pt unknown
- 2016-01-22 HU HUE16702210A patent/HUE061175T2/hu unknown
- 2016-01-22 CA CA2974041A patent/CA2974041C/en active Active
- 2016-01-22 DK DK16702210.2T patent/DK3247722T5/da active
- 2016-01-22 JP JP2017538387A patent/JP6717836B2/ja active Active
- 2016-01-22 CN CN201680017610.XA patent/CN107531761B/zh active Active
- 2016-01-22 ES ES16702210T patent/ES2937959T3/es active Active
- 2016-01-22 FI FIEP16702210.2T patent/FI3247722T3/fi active
- 2016-01-22 HR HRP20230177TT patent/HRP20230177T1/hr unknown
- 2016-01-22 WO PCT/IB2016/050335 patent/WO2016116904A1/en not_active Ceased
- 2016-01-22 BR BR112017015567A patent/BR112017015567A2/pt not_active Application Discontinuation
- 2016-01-22 MX MX2017009538A patent/MX382518B/es unknown
- 2016-01-22 EP EP16702210.2A patent/EP3247722B1/en active Active
- 2016-01-22 LT LTEPPCT/IB2016/050335T patent/LT3247722T/lt unknown
- 2016-01-22 AU AU2016210548A patent/AU2016210548B2/en not_active Ceased
- 2016-01-22 SG SG11201705740UA patent/SG11201705740UA/en unknown
- 2016-01-22 BE BE2016/5050A patent/BE1023087B1/fr not_active IP Right Cessation
- 2016-01-22 US US15/544,730 patent/US10167321B2/en active Active
- 2016-01-22 EA EA201791562A patent/EA038250B1/ru unknown
-
2017
- 2017-07-09 IL IL253366A patent/IL253366B/en unknown
- 2017-07-19 ZA ZA2017/04912A patent/ZA201704912B/en unknown
-
2018
- 2018-09-10 AU AU2018226521A patent/AU2018226521B2/en not_active Ceased
- 2018-11-15 US US16/192,347 patent/US20190276498A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504117A5 (enExample) | ||
| HRP20230177T1 (hr) | Antigeni citomegalovirusa i njihove uporabe | |
| CN107434827B (zh) | 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 | |
| JP2009540801A5 (enExample) | ||
| CN102747047B (zh) | 人乳头瘤病毒型别杂合病毒样颗粒及其制备方法 | |
| RU2019139064A (ru) | Композиции и способы для лечения цитомегаловируса | |
| JP2011087580A5 (enExample) | ||
| JP2010227101A5 (enExample) | ||
| JP2014500724A5 (enExample) | ||
| US20220152189A1 (en) | Hpv vaccine | |
| TWI621627B (zh) | 用於豬生殖與呼吸綜合症及豬環狀病毒關聯疾病之疫苗組成物 | |
| JP2017503482A5 (enExample) | ||
| JP2016534034A5 (enExample) | ||
| KR102351259B1 (ko) | 58형 인유두종 바이러스 엘1 단백질의 돌연변이체 | |
| RU2010111725A (ru) | Рекомбинантный герпесвирус кои (khv) или герпесвирус 3 семейства карповых (cyhv-3) и вакцина для профилактики заболевания, вызванного khv/cyhv-3 у cyprinus carpio или cyprinus carpio koi | |
| CN109776657B (zh) | 重组诺如病毒vlp颗粒和制备方法及其用途 | |
| HRP20200418T1 (hr) | Terapeutska uporaba koštanih morfogenetičkih proteina | |
| JP2019511921A5 (enExample) | ||
| CN118272396A (zh) | 用于预防或治疗hpv感染相关疾病的多核苷酸分子 | |
| CN106831959A (zh) | 一种人乳头瘤病毒33型l1蛋白的突变体 | |
| KR102803235B1 (ko) | 타입 39 인유두종 바이러스 l1 단백질의 돌연변이체 | |
| RU2015100211A (ru) | Химерные белки на основе cyaa, включающие гетерологичный полипептид, и их применение в индукции имунного ответа | |
| JP7224332B2 (ja) | ヒトパピローマウイルス１６型のｌ１タンパク質の変異体 | |
| JP2022505094A5 (enExample) | ||
| JP2015524420A5 (enExample) |